Description
Semax was developed as a stabilized analogue of a short adrenocorticotropic hormone sequence, with modifications that enhance metabolic stability while retaining central nervous system activity. In preclinical and clinical research from Russia and Eastern Europe, Semax has been examined for its effects on learning, memory, and recovery from ischemic and traumatic insults, making it a widely studied neuropeptide tool.
Mechanistic studies indicate that Semax can modulate BDNF expression, monoamine neurotransmitter systems, and enkephalin-degrading enzymes, as well as genes linked to synaptic plasticity and neuroprotection. Its ACTH-related origin also connects it to melanocortin receptor signaling, and work in rodent models has explored downstream changes in inflammatory and stress-response markers.
